

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 0 8 2002

Examiner: Not Yet Assigned TECH CENTER 1600/2900

Group Art Unit: 1645

In re Application for:

H. Michael SHEPARD et al.

Serial No.: 09/910,345

Filing Date: July 20, 2001

For: METHODS FOR IDENTIFYING

THERAPEUTIC TARGETS FOR TREATING INFECTIOUS DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

	This Information Disclosure Statement is submitted:
	With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
X	Within three months of the application filing date or before receipt of a first Office
	Action on the merits; accordingly, no fee or separate requirements are required.
	Before the mailing date of the first Office Action on the merits. In the event, however
	that an Office Action has crossed in the mail with this Information Disclosure
	Statement, the Commissioner is hereby authorized to charge Deposit Account
	No. 50-1189 for any fees required pursuant to 37 C F R 88 1 17(p) or 1 17(i)(1)

- After receipt of a first Office A After receipt of a final Office Action or Notice or nat Office Action of the issue fee. Accordingly, a Certific of the issue fee. Notice of Allowance. A fee is: the issue fee. Accordingly, a Certification under 37 C.F.A. T. herein. The Commissioner is hereby authorized.

 No. 50-1100 c charge Deposit Account No. 50-11 §§ 1.17(p) or 1.17(i)(1). herein. The Commissioner is hereby authorized to charge Deposit, of No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.170.
 - Each item of information contained in the Information Disclosure Statement was first The undersigned certifies that: cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information 図
 - No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1178** referencing 23896-7101. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated:

Bv:

Antoinette F. Konski

Registration No. 34,202

Bingham McCutchen LLP (formerly McCutchen Doyle Brown & Enersen LLP)

Three Embarcadero Center, Suite 1800 San Francisco, California 94111-4067

Telephone: (650) 849-4950 Facsimile: (650) 849-4800

PTO/SB/08A (10-01)
Approved for a through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known		
Application Number	09/910,345	
Filing Date	July 20, 2001	
First Named Inventor	H.Michael SHEPARD	
Art Unit	1645	
Examiner Name	Not Yet Assigned	
Attorney Docket Number	NB 2017.00	

	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or	
Initials*	No. ¹	Number – Kind Code ² (if known)	MM-DD-YY	Application of Cited Document	Relevant Figures Appear	
	·	US-			DE	
		US-			HECFIVED	
		US-			- CIVED	
 		US-			AUG 0 8 2002	
		US-			700 0 8 2002	
		US-			TECH CENTER	
		US-			JEUN CENTER 1800/200	
		US-			1,000/290	
		US-				
		US-				
		US-				
		US-			 	
		US-				
		US-			<u> </u>	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite Foreign Patent Document No.1 Country Code3 – Number4 – Kind Code5 (if known)	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials*		MM-DD-YY	Application of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶	
	1	WO 99/08110	02-18-99	NewBiotics, Inc.		├
	2	WO 99/37753	07-28-99	NewBiotics, Inc.		┼—
	3	WO 01/07087	02-01-00	NewBiotics, Inc.		↓—
	4	WO 01/07088	02-01-01	NewBiotics, Inc.		↓
	5	WO 01/64687	09-07-01	NewBiotics, Inc.		↓
	6	WO 01/83492	11-08-01	NewBiotics, Inc.		 -
						\vdash
					+	+-

Examiner's Signature	Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner's

Signature

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Compi	lete if Known
Application Number	09/910,345
Filing Date	July 20, 2001
First Named Inventor	H. Michael SHEPARD
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2017.00

	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
1	BOYER, C. et al. "NB1011, a novel drug that targets tumor cells overexpressing thymidilate synthase, induces p21, BAX and GADD45 and blocks G2/M cell cycle progression in MCF7TDX cells" 92 nd Proceedings of the American Assc. for Cancer Research Annual Meeting, Annual Meeting of the American Assn. for Cancer Research (March 2001) 42:507-508	
2	LI, Q. et al. "A novel approach to thymidylate synthase as a target for cancer chemotherapy" <i>Mol. Pharm.</i> (2001) 59(3):446-452	
3	SMYTH, T.P. et al. "S-aminosulfeniminopenicillins: Multimode. β-lactamase inhibitors and template structure for penicillin-based β-lactamase substrates as prodrugs" <i>J. Org. Chem.</i> (1998) 63(22) :7600-7618	
	RECEIVE	FD
	AUG 0 8 200	
	TECH CENTER 1600	
	11000/.	¥900
	No. ¹ 1	 Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published BOYER, C. et al. "NB1011, a novel drug that targets tumor cells overexpressing thymidilate synthase, induces p21, BAX and GADD45 and blocks G2/M cell cycle progression in MCF7TDX cells" 92nd Proceedings of the American Assc. for Cancer Research Annual Meeting, Annual Meeting of the American Assn. for Cancer Research (March 2001) 42:507-508 LI, Q. et al. "A novel approach to thymidylate synthase as a target for cancer chemotherapy" Mol. Pharm. (2001) 59(3):446-452 SMYTH, T.P. et al. "S-aminosulfeniminopenicillins: Multimode. β-lactamase inhibitors and template structure for

2

Date

Considered

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.